|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chan DS, Lau R, Aune D, Vieira R,
Greenwood DC, Kampman E and Norat T: Red and processed meat and
colorectal cancer incidence: Meta-analysis of prospective studies.
PLoS One. 6:e204562011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fedirko V, Tramacere I, Bagnardi V, Rota
M, Scotti L, Islami F, Negri E, Straif K, Romieu I, La Vecchia C,
et al: Alcohol drinking and colorectal cancer risk: An overall and
dose-response meta-analysis of published studies. Ann Oncol.
22:1958–1972. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jo A and Oh H: Incidence of colon cancer
related to cigarette smoking and alcohol consumption in adults with
metabolic syndrome: Prospective cohort study. J Korean Acad Nurs.
49:713–723. 2019.In Korean. View Article : Google Scholar
|
|
5
|
von Roon AC, Reese G, Teare J,
Constantinides V, Darzi AW and Tekkis PP: The risk of cancer in
patients with Crohn's disease. Dis Colon Rectum. 50:839–855. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou
Y and Qin H: Obesity and risk of colorectal cancer: A systematic
review of prospective studies. PLoS One. 8:e539162013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang Y, Ben Q, Shen H, Lu W, Zhang Y and
Zhu J: Diabetes mellitus and incidence and mortality of colorectal
cancer: A systematic review and meta-analysis of cohort studies.
Eur J Epidemiol. 26:863–876. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taylor DP, Burt RW, Williams MS, Haug PJ
and Cannon-Albright LA: Population-based family history-specific
risks for colorectal cancer: A constellation approach.
Gastroenterology. 138:877–885. 2010. View Article : Google Scholar
|
|
9
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bahnassy AA, Zekri AR, Salem SE, Abou-Bakr
AA, Sakr MA, Abdel-Samiaa AG and Al-Bradei M: Differential
expression of p53 family proteins in colorectal adenomas and
carcinomas: Prognostic and predictive values. Histol Histopathol.
29:207–216. 2014.
|
|
11
|
Mody K, Baldeo C and Bekaii-Saab T:
Antiangiogenic therapy in colorectal cancer. Cancer J. 24:165–170.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chibaudel B, Tournigand C, Bonnetain F,
Richa H, Benetkiewicz M, André T and de Gramont A: Therapeutic
strategy in unresectable metastatic colorectal cancer: An updated
review. Ther Adv Med Oncol. 7:153–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar
|
|
14
|
Kozovska Z, Gabrisova V and Kucerova L:
Colon cancer: Cancer stem cells markers, drug resistance and
treatment. Biomed Pharmacother. 68:911–916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Braun MS and Seymour MT: Balancing the
efficacy and toxicity of chemotherapy in colorectal cancer. Ther
Adv Med Oncol. 3:43–52. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soueidy C, Skaff S, Stephan F and Kattan
J: Cetuximab severe cutaneous toxicity a gateway for bacteremia:
Case report. Anticancer Drugs. 34:187–189. 2023. View Article : Google Scholar
|
|
17
|
Hu CY, Chan W, Delclos GP and Du XL:
Adjuvant chemotherapy and risk of gastrointestinal, hematologic,
and cardiac toxicities in elderly patients with stage III colon
cancer. Am J Clin Oncol. 35:228–236. 2012. View Article : Google Scholar
|
|
18
|
Cai Y, Zhang C, Hao L, Chen J, Xie P and
Chen Z: Systematic identification of seven ribosomal protein genes
in bighead carp and their expression in response to microcystin-LR.
J Toxicol Sci. 41:293–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Montanaro L, Treré D and Derenzini M:
Nucleolus, ribosomes, and cancer. Am J Pathol. 173:301–310. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Derenzini M, Montanaro L and Trerè D:
Ribosome biogenesis and cancer. Acta Histochem. 119:190–197. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Donati G, Bertoni S, Brighenti E, Vici M,
Treré D, Volarevic S, Montanaro L and Derenzini M: The balance
between rRNA and ribosomal protein synthesis up- and downregulates
the tumour suppressor p53 in mammalian cells. Oncogene.
30:3274–3288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baik IH, Jo GH, Seo D, Ko MJ, Cho CH, Lee
MG and Lee YH: Knockdown of RPL9 expression inhibits colorectal
carcinoma growth via the inactivation of Id-1/NF-κB signaling axis.
Int J Oncol. 49:1953–1962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ko MJ, Seo YR, Seo D, Park SY, Seo JH,
Jeon EH, Kim SW, Park KU, Koo DB, Kim S, et al: RPL17 promotes
colorectal cancer proliferation and stemness through ERK and
NEK2/β-catenin signaling pathways. J Cancer. 13:2570–2583. 2022.
View Article : Google Scholar :
|
|
24
|
Liu F, Li Y, Yu Y, Fu S and Li P: Cloning
of novel tumor metastasis-related genes from the highly metastatic
human lung adenocarcinoma cell line Anip973. J Genet Genomics.
34:189–195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dave B, Gonzalez DD, Liu ZB, Li X, Wong H,
Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, et al:
Role of RPL39 in metaplastic breast cancer. J Natl Cancer Inst.
109:djw2922016. View Article : Google Scholar
|
|
26
|
Hide T, Shibahara I, Inukai M, Shigeeda R
and Kumabe T: Ribosomes and ribosomal proteins promote plasticity
and stemness induction in glioma cells via reprogramming. Cells.
11:21422022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sim EU, Bong IP, Balraj P, Tan SK, Jamal
R, Sagap I, Nadeson S, Rose IM and Lom PKM: A preliminary study of
differentially expressed genes in Malaysian colorectal carcinoma
cases. Trop Life Sci Res. 17:19–37. 2006.
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
McHugh ML: Multiple comparison analysis
testing in ANOVA. Biochem Med (Zagreb). 21:203–209. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Riccardi C and Nicoletti I: Analysis of
apoptosis by propidium iodide staining and flow cytometry. Nat
Protoc. 1:1458–1461. 2006. View Article : Google Scholar
|
|
31
|
Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao
QF, Zong YP, Feng B, Zheng MH and Lu AG: Polo-like kinase 1 is
overexpressed in colorectal cancer and participates in the
migration and invasion of colorectal cancer cells. Med Sci Monit.
18:BR237–BR246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gutteridge RE, Ndiaye MA, Liu X and Ahmad
N: Plk1 inhibitors in cancer therapy: From laboratory to clinics.
Mol Cancer Ther. 15:1427–1435. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bhosale PB, Vetrivel P, Ha SE, Kim HH, Heo
JD, Won CK, Kim SM and Kim GS: Iridin Induces G2/M phase cell cycle
arrest and extrinsic apoptotic cell death through PI3K/AKT
signaling pathway in AGS gastric cancer cells. Molecules.
26:28022021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Z, Zhang G, Gao Z, Li S, Li Z, Bi J,
Liu X, Li Z and Kong C: Comprehensive analysis of differentially
expressed genes associated with PLK1 in bladder cancer. BMC Cancer.
17:8612017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song R, Hou G, Yang J, Yuan J, Wang C,
Chai T and Liu Z: Effects of PLK1 on proliferation, invasion and
metastasis of gastric cancer cells through epithelial-mesenchymal
transition. Oncol Lett. 16:5739–5744. 2018.PubMed/NCBI
|
|
36
|
Wu ZY and Wei N: Knockdown of PLK1
inhibits invasion and promotes apoptosis in glioma cells through
regulating autophagy. Eur Rev Med Pharmacol Sci. 22:2723–2733.
2018.PubMed/NCBI
|
|
37
|
Gao J, Yang T, Wang X, Zhang Y, Wang J,
Zhang B, Tang D, Liu Y, Gao T, Lin Q, et al: Identification and
characterization of a subpopulation of CD133+ cancer
stem-like cells derived from SK-UT-1 cells. Cancer Cell Int.
21:1572021. View Article : Google Scholar
|
|
38
|
Asadzadeh Z, Mansoori B, Mohammadi A,
Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A,
Brunetti O, Safaei S, et al: The combination effect of Prominin1
(CD133) suppression and Oxaliplatin treatment in colorectal cancer
therapy. Biomed Pharmacother. 137:1113642021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Francescangeli F, Patrizii M, Signore M,
Federici G, Di Franco S, Pagliuca A, Baiocchi M, Biffoni M, Ricci
Vitiani L, Todaro M, et al: Proliferation state and polo-like
kinase1 dependence of tumorigenic colon cancer cells. Stem Cells.
30:1819–1830. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Grinshtein N, Datti A, Fujitani M, Uehling
D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R and Kaplan
DR: Small molecule kinase inhibitor screen identifies polo-like
kinase 1 as a target for neuroblastoma tumor-initiating cells.
Cancer Res. 71:1385–1395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takahashi T, Sano B, Nagata T, Kato H,
Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S: Polo-like
kinase 1 (PLK1) is overexpressed in primary colorectal cancers.
Cancer Sci. 94:148–152. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Golsteyn RM, Lane HA, Mundt KE, Arnaud L
and Nigg EA: The family of polo-like kinases. Prog Cell Cycle Res.
2:107–114. 1996.PubMed/NCBI
|
|
43
|
Maire V, Némati F, Richardson M,
Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost
B, De Koning L, Lang G, et al: Polo-like kinase 1: A potential
therapeutic option in combination with conventional chemotherapy
for the management of patients with triple-negative breast cancer.
Cancer Res. 73:813–823. 2013. View Article : Google Scholar
|
|
44
|
Zhang G, Zhang Z and Liu Z: Polo-like
kinase 1 is overexpressed in renal cancer and participates in the
proliferation and invasion of renal cancer cells. Tumour Biol.
34:1887–1894. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
He ZL, Zheng H, Lin H, Miao XY and Zhong
DW: Overexpression of polo-like kinase1 predicts a poor prognosis
in hepatocellular carcinoma patients. World J Gastroenterol.
15:4177–4182. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yoon HE, Kim SA, Choi HS, Ahn MY, Yoon JH
and Ahn SG: Inhibition of Plk1 and Pin1 by 5′-nitro-indirubinoxime
suppresses human lung cancer cells. Cancer Lett. 316:97–104. 2012.
View Article : Google Scholar
|
|
47
|
van de Weerdt BC and Medema RH: Polo-like
kinases: A team in control of the division. Cell Cycle. 5:853–864.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu X and Erikson RL: Polo-like kinase
(Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad
Sci USA. 100:5789–5794. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Spänkuch B, Kurunci-Csacsko E, Kaufmann M
and Strebhardt K: Rational combinations of siRNAs targeting Plk1
with breast cancer drugs. Oncogene. 26:5793–5807. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gavet O and Pines J: Activation of cyclin
B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at
mitosis. J Cell Biol. 189:247–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hsiao YC, Hsieh YS, Kuo WH, Chiou HL, Yang
SF, Chiang WL and Chu SC: The tumor-growth inhibitory activity of
flavanone and 2′-OH flavanone in vitro and in vivo through
induction of cell cycle arrest and suppression of cyclins and CDKs.
J Biomed Sci. 14:107–119. 2007. View Article : Google Scholar
|
|
52
|
Kamijo T: Role of stemness-related
molecules in neuroblastoma. Pediatr Res. 71:511–515. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hu K, Law JH, Fotovati A and Dunn SE:
Small interfering RNA library screen identified polo-like kinase-1
(PLK1) as a potential therapeutic target for breast cancer that
uniquely eliminates tumor-initiating cells. Breast Cancer Res.
14:R222012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang H, Li W, Nan F, Ren F, Wang H, Xu Y
and Zhang F: MicroRNA expression profile of colon cancer stem-like
cells in HT29 adenocarcinoma cell line. Biochem Biophys Res Commun.
404:273–278. 2011. View Article : Google Scholar
|
